Home / Publication / Prediction of Olanzapine Exposure in Individual Patients Using Physiologically-based Pharmacokinetic Modeling and Simulation

Publication

Prediction of Olanzapine Exposure in Individual Patients Using Physiologically-based Pharmacokinetic Modeling and Simulation

Author(s): Thomas M. Polasek, Geoffrey T. Tucker, Michael J. Sorich, Michael D. Wiese, Titus Mohan, Amin Rostami-Hodjegan, Porntipa Korprasertthaworn, Vidya Perera, Andrew Rowland

Year: November 30, 2017

Recommended for you

Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials

Blog

Digital twins and virtual trials: A new era in rare disease drug development

Press Coverage

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

Publication

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

On-Demand Webinar

Prediction of Olanzapine Exposure in Individual Patients Using Physiologically-based Pharmacokinetic Modeling and Simulation

Prediction of Olanzapine Exposure in Individual Patients Using Physiologically-based Pharmacokinetic Modeling and Simulation

Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials

Digital twins and virtual trials: A new era in rare disease drug development

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Newsletter sign up

Quick links

Solutions

Contact